Literature DB >> 16209988

Obesity and clinical restenosis after coronary stent placement.

Jamal S Rana1, Murray A Mittleman, Kalon K Ho, Donald E Cutlip.   

Abstract

BACKGROUND: Obesity has been associated with improved clinical outcomes after percutaneous coronary intervention--"obesity paradox."
METHODS: We studied 6186 patients pooled from 6 major coronary stent clinical trials. Clinical restenosis was defined as target lesion revascularization (TLR) at 1 year. Body mass index was classified according to World Health Organization criteria as underweight (< 18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), obesity class I (30-34.9 kg/m2), and obesity class II/III (> or = 35 kg/m2). Multivariable logistic regression analysis was used to evaluate the effect of obesity class on TLR.
RESULTS: Compared with normal-weight patients, there was a trend to more frequent TLR in patients of obesity class II/III (13.6% vs 10.9%, P = .08). After adjustment for previously defined predictors of TLR, other than the obesity-related intermediate states of diabetes and hypertension, obesity class II/III was associated with 1.33-fold (95% CI 1.00-1.78) higher odds of TLR. In an analysis restricted to patients without diabetes or hypertension, obesity class II/III was also associated with significantly higher odds of undergoing TLR (odd ratio [OR] 2.14, 95% CI 1.21-3.77).
CONCLUSION: After coronary stenting, the odds of undergoing TLR were higher in patients with obesity class II/III compared with normal-weight patients. The significant association of severe obesity in nondiabetic and normotensive patients suggests that other obesity-associated mechanisms such as insulin resistance and inflammation should be further explored.

Entities:  

Mesh:

Year:  2005        PMID: 16209988     DOI: 10.1016/j.ahj.2004.11.022

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

1.  Matrix metalloproteinases modulated by protein kinase Cε mediate resistin-induced migration of human coronary artery smooth muscle cells.

Authors:  Qinxue Ding; Hong Chai; Nausheen Mahmood; Jerry Tsao; Daria Mochly-Rosen; Wei Zhou
Journal:  J Vasc Surg       Date:  2011-01-31       Impact factor: 4.268

2.  A comparative study of restenosis rates in bare metal and drug-eluting stents.

Authors:  Shilpi Mohan; Anil Dhall
Journal:  Int J Angiol       Date:  2010

3.  Impact of metabolic syndrome and C-reactive protein on outcome after coronary stenting.

Authors:  G R Iturry-Yamamoto; A C Zago; E H Moriguchi; W C Manfroi; J L Camargo; J L Gross; A J Zago
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

4.  Effect of body mass index on Argatroban therapy during percutaneous coronary intervention.

Authors:  Marcie J Hursting; Ik-Kyung Jang
Journal:  J Thromb Thrombolysis       Date:  2007-05-28       Impact factor: 2.300

5.  Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries.

Authors:  Ke-Qing Shi; Fa-Ling Wu; Wen-Yue Liu; Chen-Chen Zhao; Chang-Xi Chen; Yao-Yao Xie; Sheng-Jie Wu; Xian-Feng Lin; Yong-Ping Chen; Danny Ka-Ho Wong; Man-Fung Yuen; Ming-Hua Zheng
Journal:  Mol Biol Rep       Date:  2014-04-02       Impact factor: 2.316

6.  Association of Metabolic Phenotypes With Coronary Artery Disease and Cardiovascular Events in Patients With Stable Chest Pain.

Authors:  Andreas A Kammerlander; Thomas Mayrhofer; Maros Ferencik; Neha J Pagidipati; Julia Karady; Geoffrey S Ginsburg; Michael T Lu; Daniel O Bittner; Stefan B Puchner; Nathan A Bihlmeyer; Nandini M Meyersohn; Hamed Emami; Svati H Shah; Pamela S Douglas; Udo Hoffmann
Journal:  Diabetes Care       Date:  2021-02-08       Impact factor: 19.112

7.  C-reactive protein derived from perivascular adipose tissue accelerates injury-induced neointimal hyperplasia.

Authors:  Jia-Yuan Chen; Xiao-Lin Zhu; Wen-Hao Liu; Yong Xie; Hai-Feng Zhang; XiaoQiao Wang; Ru Ying; Zhi-Teng Chen; Mao-Xiong Wu; Qiong Qiu; Jing-Feng Wang; Yang-Xin Chen
Journal:  J Transl Med       Date:  2020-02-11       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.